Lithium Ion

Lithium Ion

SCHEMBL7085995

B.[Al+3].[HH].[Li+].[Na+]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium Ion SCHEMBL11884117 0.89
Lithium Ion SCHEMBL725902 0.80
Lithium Ion SCHEMBL3287244 0.78
SCHEMBL8149153 0.78
Lithium Ion SCHEMBL8799210 0.78
Lithium Ion SCHEMBL10681920 0.67
SCHEMBL8599079 0.67
Hydrochloric Acid SCHEMBL7874154 0.67
Lithium Ion SCHEMBL7397104 0.67
Hydrochloric Acid SCHEMBL2582276 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246909-A1 EBNA1 Inhibitors and Methods Using Same WISTAR INST (US) 2024-07-25 US disclosed
US-11912659-B2 EBNA1 inhibitors and methods using same THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2024-02-27 US disclosed
US-20220064112-A1 EBNA1 Inhibitors and Methods Using Same WISTAR INST (US) 2022-03-03 US disclosed
US-10981867-B2 EBNA1 inhibitors and methods using same THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2021-04-20 US disclosed
US-20200239415-A1 EBNA1 INHIBITORS AND METHODS USING SAME WISTAR INST (US) 2020-07-30 US disclosed
US-10442763-B2 EBNA1 inhibitors and methods using same THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2019-10-15 US disclosed
US-20180305312-A1 EBNA1 INHIBITORS AND METHODS USING SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-10-25 US disclosed
EP-3294705-A1 EBNA1 INHIBITORS AND METHODS USING SAME The Wistar Institute Of Anatomy And Biology (US) 2018-03-21 EP disclosed
WO-2016183534-A1 EBNA1 INHIBITORS AND METHODS USING SAME THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2016-11-17 WO disclosed
CN-101466725-B Amino derivatives of androstanes and androstenes as medicaments for cardiovascular disorders SIGMA TAU IND FARMACEUTI 2014-06-25 CN disclosed
CN-101466725-A Amino derivatives of androstanes and androstenes as medicaments for cardiovascular disorders SIGMA TAU IND FARMACEUTI (IT) 2009-06-24 CN disclosed
EP-1189925-B1 NEW PROCESS FOR THE SYNTHESIS OF 17BETA-HYDROXY-17ALPHA-METHYL-2-OXA-5ALPHA-ANDROSTANE-3-ONE RICHTER GEDEON VEGYESZET (HU) 2003-07-23 EP disclosed
US-6583298-B1 Ring closure and reduction of 17-hydroxy-17-methyl-1,3-seco-2-nor-5-androstane-1,3-diacid without intermediate separation RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2003-06-24 US disclosed
EP-1189925-A1 NEW PROCESS FOR THE SYNTHESIS OF 17BETA-HYDROXY-17ALPHA-METHYL-2-OXA-5ALPHA-ANDROSTANE-3-ONE RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 2002-03-27 EP disclosed
WO-2000077025-A1 NEW PROCESS FOR THE SYNTHESIS OF 17β-HYDROXY-17α-METHYL-2-OXA-5α-ANDROSTANE-3-ONE Richter Gedeon Vegyészeti Gyár Rt. (HU) 2000-12-21 WO disclosed
US-5137889-A Hypotensive agents; coronary vasodilators; calcium antagonists; antiinflammatory agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-08-11 US disclosed
US-5034395-A Hypotensive agents, carboxylated dihydropyridines OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-07-23 US disclosed
EP-0145434-A2 Novel dihydropyridine derivatives and process for preparing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1985-06-19 EP disclosed